GAL and neoplasm: Our results revealed that the novel chimeric protein PK5-RL-Gal-3C exhibited stronger anti-tumor activity and significantly prolonged the survival time of tumor-bearing mice in orthotopic mouse liver cancer model compared to PK5 or Gal-3C treatment alone.